SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001140361-24-022682
Filing Date
2024-04-29
Accepted
2024-04-29 07:00:38
Documents
15
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ef20027882_10ka.htm   iXBRL 10-K/A 618282
2 EXHIBIT 31.1 ef20027882_ex31-1.htm EX-31.1 4582
3 EXHIBIT 31.2 ef20027882_ex31-2.htm EX-31.2 4832
  Complete submission text file 0001140361-24-022682.txt   897209

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eltx-20231231.xsd EX-101.SCH 3976
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eltx-20231231_lab.xml EX-101.LAB 28964
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eltx-20231231_pre.xml EX-101.PRE 21010
19 EXTRACTED XBRL INSTANCE DOCUMENT ef20027882_10ka_htm.xml XML 7297
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

IRS No.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39990 | Film No.: 24886540
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)